Cargando…
An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG)
Desmoid-type fibromatosis is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Currently, there is no established or evidence-based treatment approach available for this disease. Therefore, in 2015 the European D...
Autores principales: | Kasper, B, Baumgarten, C, Garcia, J, Bonvalot, S, Haas, R, Haller, F, Hohenberger, P, Penel, N, Messiou, C, van der Graaf, W T, Gronchi, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834048/ https://www.ncbi.nlm.nih.gov/pubmed/28961825 http://dx.doi.org/10.1093/annonc/mdx323 |
Ejemplares similares
-
Global Patient Involvement in Sarcoma Care—A Collaborative Initiative of the Connective Tissue Oncology Society (CTOS) & Sarcoma Patients EuroNet (SPAEN)
por: Kasper, Bernd, et al.
Publicado: (2022) -
Setting the international research agenda for sarcoma together with patients and carers: first results of the Sarcoma Patient EuroNet (SPAEN) priority setting partnership
por: Husson, O., et al.
Publicado: (2022) -
Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patients—A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN)
por: Kasper, Bernd, et al.
Publicado: (2021) -
Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
por: Sleijfer, S, et al.
Publicado: (2012) -
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
por: Lindner, Lars H., et al.
Publicado: (2018)